 JERUSALEM, June 23, 2021 PRNewswire -- BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV, a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its first quarter financial results for the quarter ended March 31, 2021. 